Inogen, Inc. (NASDAQ:INGN) Ratings Summary as of Dec 6, 2018

Inogen, Inc. (NASDAQ:INGN) Corporate Logo
Big Money Sentiment decreased to 1.04 in 2018 Q2. It has change of 0.06, from 2018Q1’s 1.1. The ratio fall due to Inogen, Inc. positioning: 23 sold and 76 reduced. 42 funds acquired holdings and 61 increased holdings. Investors holded 19.84 million in 2018Q1 but now own 19.88 million shares or 0.20% more.
Moreover, Deutsche Savings Bank Ag has 0.01% invested in Inogen, Inc. (NASDAQ:INGN) for 82,824 shs. Parkside Natl Bank invested in 13 shs or 0% of the stock. Ameriprise Finance Inc accumulated 221,775 shs. Catalyst Cap Advsr Ltd Co holds 600 shs or 0% of its capital. Quantbot Tech Lp reported 0.01% stake. State Board Of Administration Of Florida Retirement System has 0.01% invested in Inogen, Inc. (NASDAQ:INGN) for 11,611 shs. 1,607 are owned by Shelton. Envestnet Asset owns 375 shs or 0% of their US capital. The Illinois-based Oberweis Asset Management has invested 1.37% in Inogen, Inc. (NASDAQ:INGN). Quantitative Investment Mgmt Lc holds 0.06% or 15,500 shs. Timessquare Capital Management Llc accumulated 217,180 shs. Great West Life Assurance Can reported 0.02% of its capital in Inogen, Inc. (NASDAQ:INGN). Hbk L P stated it has 0.01% in Inogen, Inc. (NASDAQ:INGN). Guggenheim Cap Limited accumulated 3,594 shs or 0% of the stock. Moreover, Captrust Advsrs has 0% invested in Inogen, Inc. (NASDAQ:INGN).

Inogen, Inc. (NASDAQ:INGN) Ratings Coverage

In total 2 analysts cover Inogen (NASDAQ:INGN). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:INGN) has 100% bullish analysts. 4 are the (NASDAQ:INGN)’s ratings reports on Dec 6, 2018 according to StockzIntelligence Inc. On Tuesday, November 20 Needham upgraded Inogen, Inc. (NASDAQ:INGN) rating. Needham has “Strong Buy” rating and $280 target. On Monday, September 10 the rating was downgraded by Needham to “Buy”. On Wednesday, August 22 the stock of Inogen, Inc. (NASDAQ:INGN) has “Buy” rating given by Stifel Nicolaus. In Monday, June 11 report Needham maintained the stock with “Buy” rating. Listed here are Inogen, Inc. (NASDAQ:INGN) PTs and latest ratings.

20/11/2018 Broker: Needham Old Rating: Buy New Rating: Strong Buy New Target: $280 Upgrade
10/09/2018 Broker: Needham Old Rating: Strong Buy New Rating: Buy Old Target: $254 New Target: $296 Downgrade
22/08/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $258 Maintain
11/06/2018 Broker: Needham Rating: Buy New Target: $215.0000 Maintain

The stock decreased 1.69% or $2.43 during the last trading session, hitting $141.15.Currently Inogen, Inc. is uptrending after 162.95% change in last December 6, 2017. INGN has also 234,790 shares volume. INGN outperformed the S&P500 by 147.33%.

Inogen, Inc., a medical technology company, primarily develops, makes, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally.The company has $3.04 billion market cap. The companyÂ’s oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.The P/E ratio is 76.63. It offers Inogen One systems, which are portable devices that concentrate the air around the patients to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories.

For more Inogen, Inc. (NASDAQ:INGN) news posted briefly go to:,,, or The titles are as follows: “Health Care Sector Update for 11/07/2018: FOMX,GHDX,PDLI,INGN – Nasdaq” posted on November 07, 2018, “Inogen Announces Third Quarter 2018 Financial Results – Business Wire” on November 06, 2018, “Inogen, Inc 2018 Q3 – Results – Earnings Call Slides – Seeking Alpha” with a publish date: November 08, 2018, “Inogen down 17% premarket after Q3 report, softer growth projections – Seeking Alpha” and the last “Needham doubles down on Inogen – Seeking Alpha” with publication date: November 20, 2018.

Inogen, Inc. (NASDAQ:INGN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.